Ciltacabtagene autoleucel (Carvykti®). HTA ID: 22021

Assessment Status NCPE Assessment Process Complete
HTA ID 22021
Drug Ciltacabtagene autoleucel
Brand Carvykti®
Indication For the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
Assessment Process
Rapid review commissioned 11/04/2022
Rapid review completed 12/05/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cilta-cel (ciltacabtagene autoleucel) compared with the current standard-of-care.
Full pharmacoeconomic assessment commissioned by HSE 27/05/2022
Pre-submission consultation with Applicant 12/07/2022
Full submission received from Applicant 30/11/2022
Preliminary review sent to Applicant 30/05/2023
NCPE assessment re-commenced 27/06/2023
Factual accuracy sent to Applicant 04/09/2023
NCPE assessment re-commenced 12/09/2023
NCPE assessment completed 27/09/2023
NCPE assessment outcome The NCPE recommends that cilta-cel not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.